RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial

PHASE3

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped This is a rollover study following the Lighthouse II trial; it was scheduled to stop when the LH II trial was stopped/completed. The LH II trial has been prematurely terminated so, likewise, this study has also now been stopped.

Conditions

Amyotrophic Lateral Sclerosis
ALS

Interventions

DRUG: Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)

Sponsor

Macquarie University, Australia